)
Pyxis Oncology (PYXS) investor relations material
Pyxis Oncology Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Special meeting set for November 13, 2026, to vote on doubling authorized common shares from 190 million to 380 million and on an adjournment measure; the Board recommends FOR both.
The proposed increase is intended in part to enable exercise of warrants issued in an October 1, 2026 offering and to provide share capacity for financing and other corporate needs.
Voting matters and shareholder proposals
Proposal One requires approval by a majority of outstanding common shares entitled to vote; abstentions and unvoted shares have the same effect as AGAINST votes.
Proposal Two requires a majority of shares present or represented by proxy and entitled to vote; the Board may use an approved adjournment to solicit additional votes for Proposal One.
Record date is October 8, 2026, with 119,583,637 common shares outstanding; each share carries one vote.
The November 13 meeting will be virtual; voting is available online, by phone, mail, or during the meeting after registration.
Shareholder rights and capital structure
The amendment would raise authorized common shares from 190 million to 380 million; authorized preferred shares remain 10 million.
At the record date, 119,583,637 common shares were outstanding, 39,698,811 reserved for options, RSUs and warrants, and 27,645,186 authorized shares remained unissued and unreserved.
An October 1 offering included warrants to purchase up to 49,310,352 common shares; existing authorization is insufficient for their exercise, and warrants may have no value if the amendment is not approved.
Additional share capacity could support capital raises, equity awards, acquisitions, collaborations and other purposes; future issuances may dilute earnings per share, book value and current holders’ voting interests.
The Board could issue authorized shares without further stockholder approval, subject to applicable law and Nasdaq rules; increased issuance capacity could also make a change of control more difficult.
- A novel ADC showed 36% response, 94% disease control, and manageable safety in advanced HNSCC.PYXS
Study update - Registering 39.2M shares for resale, with proceeds supporting lead oncology program advancement.PYXS
Registration filing - MICVO demonstrates high efficacy and disease control in R/M HNSCC, with pivotal data due in 2026.PYXS
Corporate presentation - MICVO clinical progress and $50M financing extend runway, but losses and liquidity risks remain.PYXS
Q2 2026 - Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancer.PYXS
Jefferies Global Healthcare Conference 2026 - MICVO demonstrates high response rates and safety advances in head and neck cancer trials.PYXS
Stifel 2026 Targeted Oncology Virtual Forum - MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping.PYXS
RBC Capital Markets Global Healthcare Conference 2026 - MICVO shows high response and disease control rates with favorable safety in HNSCC studies.PYXS
Study Update - PYX-201 achieved 50% ORR in head and neck cancer and 26% ORR across six tumor types with strong safety.PYXS
Status Update
Next Pyxis Oncology earnings date
Next Pyxis Oncology earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)